Arsenic Exposure, Genetic Determinants and Diabetes Risk in a Family Study

家庭研究中的砷暴露、遗传决定因素和糖尿病风险

基本信息

  • 批准号:
    8502498
  • 负责人:
  • 金额:
    $ 62.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-07-01 至 2016-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Background: Increasing epidemiologic and experimental evidence supports the role of inorganic arsenic in the development of diabetes. Arsenic in drinking water is a major concern for US populations who live in small rural communities. Prospective evidence and mechanisms for arsenic related diabetes must be investigated. Objective: To evaluate the role of inorganic arsenic exposure and metabolism and gene-arsenic interactions in the development of diabetes, insulin resistance, ? cell dysfunction and the metabolic syndrome among 2,717 Strong Heart Family Study (SHFS) participants e18 year old who were free of diabetes at baseline. Preliminary studies: We have identified an association between urine arsenic concentrations and the prevalence of diabetes in American Indians 45-74 year old from Arizona, Oklahoma and the Dakotas who participated in the Strong Heart Study (SHS). Urine arsenic concentrations and methylation excretion patterns remained constant over a 10-year follow-up. The heritability of the proportion of monomethylarsonate (%MMA) in urine was 0.52. In a small linkage study, we detected potential quantitative trait loci associated with %MMA in areas of the genome close to methyltransferase genes. Design and setting: The SHFS is a population- based prospective family study that recruited parents, spouses, offspring, spouses of offspring and grandchildren of SHS participants in 1998-2005. Demographic, lifestyle and medical information and measures of fasting glucose and insulin, lipid profile, hypertension endpoints, body mass index, and waist and hip circumferences are available at baseline and follow-up visits through 2011. Urine samples and blood DNA samples were stored at -70oC. Exposure assessment: We will measure total urine arsenic and urine arsenic species concentrations using inductively coupled plasma-mass spectrometry (ICPMS) and high performance liquid chromatography-ICPMS (HPLC-ICPMS), respectively. Genetic assessment: We will prioritize and measure ~1,500 SNPs in candidate genes related to arsenic metabolism and toxicity using a multiplex panel. We will measure SNPs in candidate genes related to diabetes traits using the Metabo-chip, a highly cost- effective candidate gene chip for diabetes and cardiometabolic traits. Statistical analysis: We will use mixed- effect models for binary and linear outcomes to assess the prospective association of urine arsenic species concentrations at baseline with the incidence of diabetes and the metabolic syndrome and changes in the homeostatic model assessment to quantify insulin resistance (HOMA-IR) and ? cell dysfunction (HOMA-B) over time. Gene-arsenic interaction will be estimated using principle component analysis and accounting for population stratification using genomic control. Significance: By investigating the contribution of inorganic arsenic to diabetes, insulin resistance, ? cell dysfunction and the metabolic syndrome and by identifying genetic susceptibility factors, this study can inform the arsenic-diabetes relationship and impact the prevention and control of arsenic exposure in drinking water and food in the US and abroad.
背景:越来越多的流行病学和实验证据支持无机砷在糖尿病发展中的作用。饮用水中的砷是生活在小农村社区的美国人最关心的问题。必须对砷相关糖尿病的前瞻性证据和机制进行调查。目的:探讨无机砷暴露与代谢及基因-砷相互作用在糖尿病、胰岛素抵抗、?在2,717名18岁、基线无糖尿病的强心脏家族研究(SHFS)参与者中进行细胞功能障碍和代谢综合征的研究。初步研究:我们已经确定了来自亚利桑那州、俄克拉荷马州和达科他州参加强心脏研究(SHS)的45-74岁美国印第安人尿砷浓度与糖尿病患病率之间的关联。在10年的随访中,尿砷浓度和甲基化排泄模式保持不变。尿中单甲基膦酸盐(%MMA)的遗传率为0.52。在一项小型连锁研究中,我们在基因组靠近甲基转移酶基因的区域检测到与%MMA相关的潜在数量性状位点。设计和背景:SHFS是一项基于人群的前瞻性家庭研究,在1998-2005年期间招募了SHS参与者的父母、配偶、后代、后代的配偶和孙辈。人口统计、生活方式和医疗信息以及空腹血糖和胰岛素的测量、血脂、高血压终点、体重指数、腰围和臀围在基线和2011年的随访中都是可用的。尿液样本和血液DNA样本保存在-70℃。暴露评估:我们将分别使用电感耦合等离子体质谱(ICPMS)和高效液相色谱-ICPMS (HPLC-ICPMS)测量尿总砷和尿砷种浓度。遗传评估:我们将优先考虑并使用多重面板测量与砷代谢和毒性相关的候选基因中的约1500个snp。我们将使用代谢芯片测量与糖尿病性状相关的候选基因的snp,代谢芯片是一种高成本效益的糖尿病和心脏代谢性状候选基因芯片。统计分析:我们将使用二元和线性结果的混合效应模型来评估基线时尿砷种类浓度与糖尿病和代谢综合征发生率的前瞻性关联,以及在体内平衡模型评估中量化胰岛素抵抗(HOMA-IR)和?细胞功能障碍(HOMA-B)随着时间的推移。基因与砷的相互作用将利用主成分分析进行估计,并利用基因组控制对种群分层进行核算。意义:探讨无机砷对糖尿病、胰岛素抵抗、?本研究可通过确定遗传易感因素,为砷与糖尿病的关系提供信息,并对美国及国外饮用水和食物中砷暴露的预防和控制产生影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Wen Hong Linda Kao其他文献

Wen Hong Linda Kao的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Wen Hong Linda Kao', 18)}}的其他基金

Arsenic Exposure, Genetic Determinants and Diabetes Risk in a Family Study
家庭研究中的砷暴露、遗传决定因素和糖尿病风险
  • 批准号:
    8266205
  • 财政年份:
    2012
  • 资助金额:
    $ 62.38万
  • 项目类别:
Admixture Mapping to Identify T2DM Genes in African Americans
混合图谱鉴定非裔美国人的 T2DM 基因
  • 批准号:
    7015679
  • 财政年份:
    2006
  • 资助金额:
    $ 62.38万
  • 项目类别:
Admixture Mapping to Identify T2DM Genes in African Americans
混合图谱鉴定非裔美国人的 T2DM 基因
  • 批准号:
    7229837
  • 财政年份:
    2006
  • 资助金额:
    $ 62.38万
  • 项目类别:
Identification of Genes for ESRD in African Americans
非裔美国人 ESRD 基因的鉴定
  • 批准号:
    7279104
  • 财政年份:
    2005
  • 资助金额:
    $ 62.38万
  • 项目类别:
Genetic Epidemiology of NAFLD and T2DM
NAFLD 和 T2DM 的遗传流行病学
  • 批准号:
    7027693
  • 财政年份:
    2005
  • 资助金额:
    $ 62.38万
  • 项目类别:
Identification of Genes for ESRD in African Americans
非裔美国人 ESRD 基因的鉴定
  • 批准号:
    6903033
  • 财政年份:
    2005
  • 资助金额:
    $ 62.38万
  • 项目类别:
Longtitudinal Study of Dialysis
透析的纵向研究
  • 批准号:
    8543232
  • 财政年份:
    2005
  • 资助金额:
    $ 62.38万
  • 项目类别:
Genetic Epidemiology of NAFLD and T2DM
NAFLD 和 T2DM 的遗传流行病学
  • 批准号:
    7186649
  • 财政年份:
    2005
  • 资助金额:
    $ 62.38万
  • 项目类别:
Genetic Epidemiology of NAFLD and T2DM
NAFLD 和 T2DM 的遗传流行病学
  • 批准号:
    6871918
  • 财政年份:
    2005
  • 资助金额:
    $ 62.38万
  • 项目类别:
Identification of Genes for ESRD in African Americans
非裔美国人 ESRD 基因的鉴定
  • 批准号:
    7103520
  • 财政年份:
    2005
  • 资助金额:
    $ 62.38万
  • 项目类别:

相似海外基金

Communication in American Indians thru Strategies for Equity 4 Cancer (CASE4Cancer)
美国印第安人通过公平策略进行沟通 4 癌症 (CASE4Cancer)
  • 批准号:
    10892489
  • 财政年份:
    2023
  • 资助金额:
    $ 62.38万
  • 项目类别:
Digital smoking cessation intervention for nationally-recruited American Indians and Alaska Natives: A full-scale randomized controlled trial
针对全国招募的美洲印第安人和阿拉斯加原住民的数字戒烟干预:一项全面的随机对照试验
  • 批准号:
    10826067
  • 财政年份:
    2023
  • 资助金额:
    $ 62.38万
  • 项目类别:
Medication Adherence and Cardio-Metabolic Control Indicators among Adult American Indians Receiving Tribal Health Services
接受部落卫生服务的成年美洲印第安人的药物依从性和心脏代谢控制指标
  • 批准号:
    10419967
  • 财政年份:
    2022
  • 资助金额:
    $ 62.38万
  • 项目类别:
Examination of evolving opioid misuse and overdose risk among American Indians
检查美洲印第安人中不断变化的阿片类药物滥用和过量风险
  • 批准号:
    10438466
  • 财政年份:
    2022
  • 资助金额:
    $ 62.38万
  • 项目类别:
Examination of evolving opioid misuse and overdose risk among American Indians
检查美洲印第安人中不断变化的阿片类药物滥用和过量风险
  • 批准号:
    10701719
  • 财政年份:
    2022
  • 资助金额:
    $ 62.38万
  • 项目类别:
Culturally Responsive Palliative Care Messaging for American Indians: An Efficacy Trial
针对美洲印第安人的文化响应姑息治疗信息:功效试验
  • 批准号:
    10431092
  • 财政年份:
    2022
  • 资助金额:
    $ 62.38万
  • 项目类别:
Culturally Responsive Palliative Care Messaging for American Indians: An Efficacy Trial
针对美洲印第安人的文化响应姑息治疗信息:功效试验
  • 批准号:
    10709495
  • 财政年份:
    2022
  • 资助金额:
    $ 62.38万
  • 项目类别:
Advancing Palliative Care in Northern Plains American Indians
推进北部平原美洲印第安人的姑息治疗
  • 批准号:
    10705232
  • 财政年份:
    2022
  • 资助金额:
    $ 62.38万
  • 项目类别:
Long-term consequences of SARS-CoV-2 infection and COVID-19 disease among American Indians: an ambidirectional cohort study in the Cherokee Nation
美洲印第安人中 SARS-CoV-2 感染和 COVID-19 疾病的长期后果:切罗基族的双向队列研究
  • 批准号:
    10438443
  • 财政年份:
    2022
  • 资助金额:
    $ 62.38万
  • 项目类别:
Advancing Palliative Care in Northern Plains American Indians
推进北部平原美洲印第安人的姑息治疗
  • 批准号:
    10643600
  • 财政年份:
    2022
  • 资助金额:
    $ 62.38万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了